What Anteris Technologies Global Corp. told the SEC could break it.

Under the v2v Agreements, Anteris's development agreement can be terminated if certain expenditure amounts, development milestones, or regulatory approvals are not incurred or achieved from March 31, 2027 onward, putting a key development funding/partnership at risk.

“the development agreement can be terminated if certain expenditure amounts, development milestones or regulatory approvals are not incurred or achieved from March 31, 2027 and onwards.”

Anteris is essentially pre-commercial (net sales only $1.9M, declining) with $377.3M of operating loss carryforwards; its ability to generate meaningful revenue depends entirely on obtaining regulatory clearance/approval and commercializing DurAVR THV, making it dependent on continued financing.

“Our ability to generate revenue from sales of any of our products depends heavily on the successful identification, development, regulatory clearance or approval for and eventual commercialization of any products.”

Anteris depends on single-source suppliers (e.g., Aran Biomedical for knitted materials); changing or adding vendors requires significant effort given rigorous FDA requirements, and establishing replacement sources on a timely basis could be difficult or impossible.

“A change or addition to our vendors could require significant effort due to the rigorous regulations and requirements of the FDA and other regulatory authorities. It could be difficult to establish additional or replacement sources on a timely basis or at all, which could have a material adverse effect on our business.”